Search
for
Sort by
Research 211–240 of 779
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Alopecia Areata: An Updated Review for 2023
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
- Janus kinase inhibitors for alopecia areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
- Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Could baricitinib treat frontal fibrosing alopecia and facial papules?
- Poster Presentations